Bookmark and Share
BioAssay: AID 643826

Binding affinity to human PPARalpha expressed in COS-1 by scintillation proximity assay

A series of benzimidazolone carboxylic acids and oxazolidinediones were designed and synthesized in search of selective PPARgamma modulators (SPPARgammaMs) as potential therapeutic agents for the treatment of type II diabetes mellitus (T2DM) with improved safety profiles relative to rosiglitazone and pioglitazone, the currently marketed PPARgamma full agonist drugs. Structure-activity more ..
_
   
 Tested Compounds
 Tested Compounds
All(27)
 
 
Unspecified(27)
 
 
 Tested Substances
 Tested Substances
All(27)
 
 
Unspecified(27)
 
 
 Related BioAssays
 Related BioAssays
AID: 643826
Data Source: ChEMBL (801274)
BioAssay Type: Confirmatory, Concentration-Response Relationship Observed
Depositor Category: Literature, Extracted
BioAssay Version:
Deposit Date: 2012-09-09
Modify Date: 2014-05-25

Data Table ( Complete ):           All
Target
Sequence: RecName: Full=Peroxisome proliferator-activated receptor alpha; Short=PPAR-alpha; AltName: Full=Nuclear receptor subfamily 1 group C member 1
Description ..   
Protein Family: The ligand binding domain of peroxisome proliferator-activated receptors
Comment ..   

Gene:PPARA     Related Protein 3D Structures     More BioActivity Data..
Tested Compounds:
Description:
Title: Benzimidazolones: a new class of selective peroxisome proliferator-activated receptor gamma (PPARgamma) modulators.

Abstract: A series of benzimidazolone carboxylic acids and oxazolidinediones were designed and synthesized in search of selective PPARgamma modulators (SPPARgammaMs) as potential therapeutic agents for the treatment of type II diabetes mellitus (T2DM) with improved safety profiles relative to rosiglitazone and pioglitazone, the currently marketed PPARgamma full agonist drugs. Structure-activity relationships of these potent and highly selective SPPARgammaMs were studied with a focus on their unique profiles as partial agonists or modulators. A variety of methods, such as X-ray crystallographic analysis, PPARgamma transactivation coactivator profiling, gene expression profiling, and mutagenesis studies, were employed to reveal the differential interactions of these new analogues with PPARgamma receptor in comparison to full agonists. In rodent models of T2DM, benzimidazolone analogues such as (5R)-5-(3-{[3-(5-methoxybenzisoxazol-3-yl)benzimidazol-1-yl]methyl}phenyl)-5-methyloxazolidinedione (51) demonstrated efficacy equivalent to that of rosiglitazone. Side effects, such as fluid retention and heart weight gain associated with PPARgamma full agonists, were diminished with 51 in comparison to rosiglitazone based on studies in two independent animal models.
(PMID: 22070604)
Categorized Comment
Assay Type: Binding

Assay Data Source: Scientific Literature

Target Type: Target is a single protein chain

Result Definitions
TIDNameDescriptionHistogramTypeUnit
OutcomeThe BioAssay activity outcomeOutcome
1IC50*IC50 PubChem standard valueFloatμM
2IC50 activity commentIC50 activity commentString
3IC50 standard flagIC50 standard flagInteger
4IC50 qualifierIC50 qualifierString
5IC50 published valueIC50 published valueFloatμM
6IC50 standard valueIC50 standard valueFloatnM

* Activity Concentration.

Data Table (Concise)
Classification
PageFrom: